Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective

1.2 Absolute and Proportional Quality-Adjusted Life-Year (QALY) Shortfall The AS assesses the relative value on the basis of the difference in an individual's expected future healthy life-years (i.e., QALYs), with and without a particular condition [6]. 1.4 National Institute for Health and Car...

Full description

Saved in:
Bibliographic Details
Published in:PharmacoEconomics 2024, Vol.42 (1), p.5-9
Main Authors: Coughlan, Diarmuid, Arisa, Oluwatomi, Thomson, Katie, Yu, Ge, Pearson, Fiona, Kernohan, Ashleigh, Gonzalez-Moral, Sonia Garcia, Wallace, Sheila, Rice, Stephen
Format: Article
Language:English
Subjects:
Algorithms
Breast cancer
Camptothecin
Cancer therapies
Commentary
Committees
Cost-Benefit Analysis
Decision making
Disease
Estimates
Health Administration
Health Economics
Humans
Immunoconjugates
Life expectancy
Medicine
Medicine & Public Health
Metastasis
Pharmacoeconomics and Health Outcomes
Policy research
Public Health
Quality of Life Research
Receptor, ErbB-2
Technology Assessment, Biomedical
Trastuzumab - therapeutic use
Willingness to pay
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c326t-514dc29811ff7cd415232ba4ea6e2dd8d2fa89e4fc9e0b23231e4e4449400f553
container_end_page 9
container_issue 1
container_start_page 5
container_title PharmacoEconomics
container_volume 42
creator Coughlan, Diarmuid
Arisa, Oluwatomi
Thomson, Katie
Yu, Ge
Pearson, Fiona
Kernohan, Ashleigh
Gonzalez-Moral, Sonia Garcia
Wallace, Sheila
Rice, Stephen
description 1.2 Absolute and Proportional Quality-Adjusted Life-Year (QALY) Shortfall The AS assesses the relative value on the basis of the difference in an individual's expected future healthy life-years (i.e., QALYs), with and without a particular condition [6]. 1.4 National Institute for Health and Care Excellence's (NICE'S) Preferred EQ-5D Data Source NICE requires the EQ-5D-3L value set for the reference case analysis [1, 9]. The NICE preferred mapping function was developed by the Decision Support Unit (DSU), which used the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions (EEPRU) dataset [1, 10, 11]. 2 Case Study: Trastuzumab Deruxtecan (T-DXd) Synopsis NICE invited the manufacturer (Daiichi Sankyo UK) of T-DXd (Enhertu®) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic breast cancer who have received trastuzumab and a taxane, as part of NICE'S Single Technology Appraisal (STA) process.
doi_str_mv 10.1007/s40273-023-01317-z
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2873251699</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2873251699</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-514dc29811ff7cd415232ba4ea6e2dd8d2fa89e4fc9e0b23231e4e4449400f553</originalsourceid><addsrcrecordid>eNp9kc1uEzEUhS1ERUvhBVggS2zYDPhvxjG7KA2lUluQGtaW47lOXc0fvjMVybJPXrcpILHowvKVznePZX2EvOPsE2dMf0bFhJYFE_lwyXWxe0GOONemEDl4-TizQleGHZLXiDeMsUpq8YocSq1NpZg5IncnEcEh0Cu4hRTHLb3o6xgiJBo7Ol4DvTxbLOlV7DYN0BX4665v-s2WzochuYiuoX2gq-RwnHZT69b0BNL0ewTvui90mYfUZWaOCIgtdCM9Tf000B-QcAA_xlt4Qw6CaxDePt3H5OfX5WrxrTj_fnq2mJ8XXopqLEquai_MjPMQtK8VL4UUa6fAVSDqelaL4GYGVPAG2DpnkoMCpZRRjIWylMfk4753SP2vCXC0bUQPTeM66Ce0YqalKHllTEY__Ife9NPDRzJluK64FFxlSuwpn3rEBMEOKbYubS1n9sGQ3Ruy2ZB9NGR3een9U_W0bqH-u_JHSQbkHsAcdRtI_95-pvYeS0SdZg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2917613214</pqid></control><display><type>article</type><title>Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective</title><source>LexisNexis - News &amp; Business</source><source>ABI/INFORM Global</source><source>Springer Nature</source><creator>Coughlan, Diarmuid ; Arisa, Oluwatomi ; Thomson, Katie ; Yu, Ge ; Pearson, Fiona ; Kernohan, Ashleigh ; Gonzalez-Moral, Sonia Garcia ; Wallace, Sheila ; Rice, Stephen</creator><creatorcontrib>Coughlan, Diarmuid ; Arisa, Oluwatomi ; Thomson, Katie ; Yu, Ge ; Pearson, Fiona ; Kernohan, Ashleigh ; Gonzalez-Moral, Sonia Garcia ; Wallace, Sheila ; Rice, Stephen</creatorcontrib><description>1.2 Absolute and Proportional Quality-Adjusted Life-Year (QALY) Shortfall The AS assesses the relative value on the basis of the difference in an individual's expected future healthy life-years (i.e., QALYs), with and without a particular condition [6]. 1.4 National Institute for Health and Care Excellence's (NICE'S) Preferred EQ-5D Data Source NICE requires the EQ-5D-3L value set for the reference case analysis [1, 9]. The NICE preferred mapping function was developed by the Decision Support Unit (DSU), which used the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions (EEPRU) dataset [1, 10, 11]. 2 Case Study: Trastuzumab Deruxtecan (T-DXd) Synopsis NICE invited the manufacturer (Daiichi Sankyo UK) of T-DXd (Enhertu®) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic breast cancer who have received trastuzumab and a taxane, as part of NICE'S Single Technology Appraisal (STA) process.</description><identifier>ISSN: 1170-7690</identifier><identifier>EISSN: 1179-2027</identifier><identifier>DOI: 10.1007/s40273-023-01317-z</identifier><identifier>PMID: 37796409</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Algorithms ; Breast cancer ; Camptothecin ; Cancer therapies ; Commentary ; Committees ; Cost-Benefit Analysis ; Decision making ; Disease ; Estimates ; Health Administration ; Health Economics ; Humans ; Immunoconjugates ; Life expectancy ; Medicine ; Medicine &amp; Public Health ; Metastasis ; Pharmacoeconomics and Health Outcomes ; Policy research ; Public Health ; Quality of Life Research ; Receptor, ErbB-2 ; Technology Assessment, Biomedical ; Trastuzumab - therapeutic use ; Willingness to pay</subject><ispartof>PharmacoEconomics, 2024, Vol.42 (1), p.5-9</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>Copyright Springer Nature B.V. Jan 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-514dc29811ff7cd415232ba4ea6e2dd8d2fa89e4fc9e0b23231e4e4449400f553</cites><orcidid>0000-0003-2853-3653 ; 0000-0002-5348-3750 ; 0000-0003-1626-0862 ; 0000-0003-0431-4771 ; 0000-0002-5514-3186 ; 0000-0002-9614-728X ; 0000-0002-0891-2501</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2917613214/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2917613214?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,11688,27924,27925,36060,36061,44363,74895</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37796409$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Coughlan, Diarmuid</creatorcontrib><creatorcontrib>Arisa, Oluwatomi</creatorcontrib><creatorcontrib>Thomson, Katie</creatorcontrib><creatorcontrib>Yu, Ge</creatorcontrib><creatorcontrib>Pearson, Fiona</creatorcontrib><creatorcontrib>Kernohan, Ashleigh</creatorcontrib><creatorcontrib>Gonzalez-Moral, Sonia Garcia</creatorcontrib><creatorcontrib>Wallace, Sheila</creatorcontrib><creatorcontrib>Rice, Stephen</creatorcontrib><title>Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective</title><title>PharmacoEconomics</title><addtitle>PharmacoEconomics</addtitle><addtitle>Pharmacoeconomics</addtitle><description>1.2 Absolute and Proportional Quality-Adjusted Life-Year (QALY) Shortfall The AS assesses the relative value on the basis of the difference in an individual's expected future healthy life-years (i.e., QALYs), with and without a particular condition [6]. 1.4 National Institute for Health and Care Excellence's (NICE'S) Preferred EQ-5D Data Source NICE requires the EQ-5D-3L value set for the reference case analysis [1, 9]. The NICE preferred mapping function was developed by the Decision Support Unit (DSU), which used the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions (EEPRU) dataset [1, 10, 11]. 2 Case Study: Trastuzumab Deruxtecan (T-DXd) Synopsis NICE invited the manufacturer (Daiichi Sankyo UK) of T-DXd (Enhertu®) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic breast cancer who have received trastuzumab and a taxane, as part of NICE'S Single Technology Appraisal (STA) process.</description><subject>Algorithms</subject><subject>Breast cancer</subject><subject>Camptothecin</subject><subject>Cancer therapies</subject><subject>Commentary</subject><subject>Committees</subject><subject>Cost-Benefit Analysis</subject><subject>Decision making</subject><subject>Disease</subject><subject>Estimates</subject><subject>Health Administration</subject><subject>Health Economics</subject><subject>Humans</subject><subject>Immunoconjugates</subject><subject>Life expectancy</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metastasis</subject><subject>Pharmacoeconomics and Health Outcomes</subject><subject>Policy research</subject><subject>Public Health</subject><subject>Quality of Life Research</subject><subject>Receptor, ErbB-2</subject><subject>Technology Assessment, Biomedical</subject><subject>Trastuzumab - therapeutic use</subject><subject>Willingness to pay</subject><issn>1170-7690</issn><issn>1179-2027</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>M0C</sourceid><recordid>eNp9kc1uEzEUhS1ERUvhBVggS2zYDPhvxjG7KA2lUluQGtaW47lOXc0fvjMVybJPXrcpILHowvKVznePZX2EvOPsE2dMf0bFhJYFE_lwyXWxe0GOONemEDl4-TizQleGHZLXiDeMsUpq8YocSq1NpZg5IncnEcEh0Cu4hRTHLb3o6xgiJBo7Ol4DvTxbLOlV7DYN0BX4665v-s2WzochuYiuoX2gq-RwnHZT69b0BNL0ewTvui90mYfUZWaOCIgtdCM9Tf000B-QcAA_xlt4Qw6CaxDePt3H5OfX5WrxrTj_fnq2mJ8XXopqLEquai_MjPMQtK8VL4UUa6fAVSDqelaL4GYGVPAG2DpnkoMCpZRRjIWylMfk4753SP2vCXC0bUQPTeM66Ce0YqalKHllTEY__Ife9NPDRzJluK64FFxlSuwpn3rEBMEOKbYubS1n9sGQ3Ruy2ZB9NGR3een9U_W0bqH-u_JHSQbkHsAcdRtI_95-pvYeS0SdZg</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Coughlan, Diarmuid</creator><creator>Arisa, Oluwatomi</creator><creator>Thomson, Katie</creator><creator>Yu, Ge</creator><creator>Pearson, Fiona</creator><creator>Kernohan, Ashleigh</creator><creator>Gonzalez-Moral, Sonia Garcia</creator><creator>Wallace, Sheila</creator><creator>Rice, Stephen</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>4T-</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>L.-</scope><scope>L.0</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2853-3653</orcidid><orcidid>https://orcid.org/0000-0002-5348-3750</orcidid><orcidid>https://orcid.org/0000-0003-1626-0862</orcidid><orcidid>https://orcid.org/0000-0003-0431-4771</orcidid><orcidid>https://orcid.org/0000-0002-5514-3186</orcidid><orcidid>https://orcid.org/0000-0002-9614-728X</orcidid><orcidid>https://orcid.org/0000-0002-0891-2501</orcidid></search><sort><creationdate>2024</creationdate><title>Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective</title><author>Coughlan, Diarmuid ; Arisa, Oluwatomi ; Thomson, Katie ; Yu, Ge ; Pearson, Fiona ; Kernohan, Ashleigh ; Gonzalez-Moral, Sonia Garcia ; Wallace, Sheila ; Rice, Stephen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-514dc29811ff7cd415232ba4ea6e2dd8d2fa89e4fc9e0b23231e4e4449400f553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Algorithms</topic><topic>Breast cancer</topic><topic>Camptothecin</topic><topic>Cancer therapies</topic><topic>Commentary</topic><topic>Committees</topic><topic>Cost-Benefit Analysis</topic><topic>Decision making</topic><topic>Disease</topic><topic>Estimates</topic><topic>Health Administration</topic><topic>Health Economics</topic><topic>Humans</topic><topic>Immunoconjugates</topic><topic>Life expectancy</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metastasis</topic><topic>Pharmacoeconomics and Health Outcomes</topic><topic>Policy research</topic><topic>Public Health</topic><topic>Quality of Life Research</topic><topic>Receptor, ErbB-2</topic><topic>Technology Assessment, Biomedical</topic><topic>Trastuzumab - therapeutic use</topic><topic>Willingness to pay</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Coughlan, Diarmuid</creatorcontrib><creatorcontrib>Arisa, Oluwatomi</creatorcontrib><creatorcontrib>Thomson, Katie</creatorcontrib><creatorcontrib>Yu, Ge</creatorcontrib><creatorcontrib>Pearson, Fiona</creatorcontrib><creatorcontrib>Kernohan, Ashleigh</creatorcontrib><creatorcontrib>Gonzalez-Moral, Sonia Garcia</creatorcontrib><creatorcontrib>Wallace, Sheila</creatorcontrib><creatorcontrib>Rice, Stephen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Global News &amp; ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Proquest Health &amp; Medical Complete</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ABI/INFORM Global</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>PharmacoEconomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Coughlan, Diarmuid</au><au>Arisa, Oluwatomi</au><au>Thomson, Katie</au><au>Yu, Ge</au><au>Pearson, Fiona</au><au>Kernohan, Ashleigh</au><au>Gonzalez-Moral, Sonia Garcia</au><au>Wallace, Sheila</au><au>Rice, Stephen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective</atitle><jtitle>PharmacoEconomics</jtitle><stitle>PharmacoEconomics</stitle><addtitle>Pharmacoeconomics</addtitle><date>2024</date><risdate>2024</risdate><volume>42</volume><issue>1</issue><spage>5</spage><epage>9</epage><pages>5-9</pages><issn>1170-7690</issn><eissn>1179-2027</eissn><abstract>1.2 Absolute and Proportional Quality-Adjusted Life-Year (QALY) Shortfall The AS assesses the relative value on the basis of the difference in an individual's expected future healthy life-years (i.e., QALYs), with and without a particular condition [6]. 1.4 National Institute for Health and Care Excellence's (NICE'S) Preferred EQ-5D Data Source NICE requires the EQ-5D-3L value set for the reference case analysis [1, 9]. The NICE preferred mapping function was developed by the Decision Support Unit (DSU), which used the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions (EEPRU) dataset [1, 10, 11]. 2 Case Study: Trastuzumab Deruxtecan (T-DXd) Synopsis NICE invited the manufacturer (Daiichi Sankyo UK) of T-DXd (Enhertu®) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic breast cancer who have received trastuzumab and a taxane, as part of NICE'S Single Technology Appraisal (STA) process.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>37796409</pmid><doi>10.1007/s40273-023-01317-z</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-2853-3653</orcidid><orcidid>https://orcid.org/0000-0002-5348-3750</orcidid><orcidid>https://orcid.org/0000-0003-1626-0862</orcidid><orcidid>https://orcid.org/0000-0003-0431-4771</orcidid><orcidid>https://orcid.org/0000-0002-5514-3186</orcidid><orcidid>https://orcid.org/0000-0002-9614-728X</orcidid><orcidid>https://orcid.org/0000-0002-0891-2501</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1170-7690
ispartof PharmacoEconomics, 2024, Vol.42 (1), p.5-9
issn 1170-7690
1179-2027
language eng
recordid cdi_proquest_miscellaneous_2873251699
source LexisNexis - News & Business; ABI/INFORM Global; Springer Nature
subjects Algorithms
Breast cancer
Camptothecin
Cancer therapies
Commentary
Committees
Cost-Benefit Analysis
Decision making
Disease
Estimates
Health Administration
Health Economics
Humans
Immunoconjugates
Life expectancy
Medicine
Medicine & Public Health
Metastasis
Pharmacoeconomics and Health Outcomes
Policy research
Public Health
Quality of Life Research
Receptor, ErbB-2
Technology Assessment, Biomedical
Trastuzumab - therapeutic use
Willingness to pay
title Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T00%3A06%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Disease%20Severity%20Modifier%20in%20the%20NICE%20Single%20Technology%20Appraisal%20of%20Trastuzumab%20Deruxtecan:%20External%20Assessment%20Group%20Perspective&rft.jtitle=PharmacoEconomics&rft.au=Coughlan,%20Diarmuid&rft.date=2024&rft.volume=42&rft.issue=1&rft.spage=5&rft.epage=9&rft.pages=5-9&rft.issn=1170-7690&rft.eissn=1179-2027&rft_id=info:doi/10.1007/s40273-023-01317-z&rft_dat=%3Cproquest_cross%3E2873251699%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c326t-514dc29811ff7cd415232ba4ea6e2dd8d2fa89e4fc9e0b23231e4e4449400f553%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2917613214&rft_id=info:pmid/37796409&rfr_iscdi=true